At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
APRE Aprea Therapeutics, Inc.
Trading 01-13 12:00:59 EST
0.9025
-0.0175
-1.90%
High0.9499Low0.9025Vol63.10K
Open0.9499D1 Closing0.9200Amplitude5.15%
Mkt Cap6.31MTradable Cap4.12MTotal Shares6.99M
T/O58.20KT/O Rate1.38%Tradable Shares4.56M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart
Reuters  ·  2025-12-22
U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart
Aprea Therapeutics Inc - Files Prospectus for Resale of 5.5 Mln Shares by the Selling Stockholders - SEC Filing
THOMSON REUTERS  ·  2025-12-20
Aprea Therapeutics Inc - Files Prospectus for Resale of 5.5 Mln Shares by the Selling Stockholders - SEC Filing
Aprea Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $5 From $20
THOMSON REUTERS  ·  2025-12-19
Aprea Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $5 From $20
BRIEF-Aprea Therapeutics CEO Issues Letter To Shareholders Highlighting Outlook For 2026
Reuters  ·  2025-12-18
BRIEF-Aprea Therapeutics CEO Issues Letter To Shareholders Highlighting Outlook For 2026
Aprea Therapeutics Inc - Pauses Enrollment in Aboya-119 Study Monotherapy Arms
THOMSON REUTERS  ·  2025-12-18
Aprea Therapeutics Inc - Pauses Enrollment in Aboya-119 Study Monotherapy Arms
Director Marc Duey Reports Acquisition of Common Shares in Aprea Therapeutics Inc
Reuters  ·  2025-12-11
Director Marc Duey Reports Acquisition of Common Shares in Aprea Therapeutics Inc
Aprea Therapeutics CFO John P. Hamill Reports Acquisition of Common Shares
Reuters  ·  2025-12-11
Aprea Therapeutics CFO John P. Hamill Reports Acquisition of Common Shares
Aprea Therapeutics Inc - Net Proceeds Expected to Fund Aprea Into 2027
THOMSON REUTERS  ·  2025-12-09
Aprea Therapeutics Inc - Net Proceeds Expected to Fund Aprea Into 2027
Press Release: Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Dow Jones  ·  2025-12-09
Press Release: Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Aprea Therapeutics Reports Continued Clinical Progress and Extends Cash Runway Into Q4 2026
Reuters  ·  2025-11-12
Aprea Therapeutics Reports Continued Clinical Progress and Extends Cash Runway Into Q4 2026
Aprea Therapeutics Advances WEE1 Inhibitor APR-1051 in Phase 1 Trial for Hard-to-Treat Cancers
Reuters  ·  2025-11-12
Aprea Therapeutics Advances WEE1 Inhibitor APR-1051 in Phase 1 Trial for Hard-to-Treat Cancers
Aprea Therapeutics Inc - Has Cash Runway Into Q4 2026
THOMSON REUTERS  ·  2025-11-12
Aprea Therapeutics Inc - Has Cash Runway Into Q4 2026
Aprea Therapeutics Q3 Net Income USD -3 Million
THOMSON REUTERS  ·  2025-11-12
Aprea Therapeutics Q3 Net Income USD -3 Million
BRIEF-Aprea Sees Early Activity in APR-1051 Wee1 Trial
Reuters  ·  2025-10-24
BRIEF-Aprea Sees Early Activity in APR-1051 Wee1 Trial
Aprea Therapeutics Provides Clinical Update From Acesot-1051 Trial Showing Early Signals of Activity for Wee1 Kinase Inhibitor Apr-1051
THOMSON REUTERS  ·  2025-10-24
Aprea Therapeutics Provides Clinical Update From Acesot-1051 Trial Showing Early Signals of Activity for Wee1 Kinase Inhibitor Apr-1051
Aprea Therapeutics Inc - No Dose Limiting Toxicities or Unexpected Safety Issues Reported
THOMSON REUTERS  ·  2025-10-24
Aprea Therapeutics Inc - No Dose Limiting Toxicities or Unexpected Safety Issues Reported
Aprea Therapeutics Inc - Dose Escalation Continues With 150 Mg Cohort Enrollment
THOMSON REUTERS  ·  2025-10-24
Aprea Therapeutics Inc - Dose Escalation Continues With 150 Mg Cohort Enrollment
Aprea Therapeutics Announces Presentations at Eortc-Nci-Aacr International Conference on Molecular Targets and Cancer Therapeutics
THOMSON REUTERS  ·  2025-10-14
Aprea Therapeutics Announces Presentations at Eortc-Nci-Aacr International Conference on Molecular Targets and Cancer Therapeutics
Aprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Reuters  ·  2025-08-12
Aprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aprea Therapeutics Reports Q2 2025 Results: Net Loss Narrows to $3.2M, EPS Improves to $0.53 from $0.58
Reuters  ·  2025-08-12
Aprea Therapeutics Reports Q2 2025 Results: Net Loss Narrows to $3.2M, EPS Improves to $0.53 from $0.58

Introduction

Company Name.
Aprea Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Issue price:
--